AT-752 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses AT-752 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- AT-752
- 3
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses AT-752 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of AT-752 in Patients With Dengue InfectionTerminatedPhase 2Atea Pharmaceuticals, Inc.NCT05466240Written as AT-752
- Study of AT-752 in Healthy Subjects in a Dengue Human Challenge ModelTerminatedPhase 1Atea Pharmaceuticals, Inc.NCT05366439Written as AT-752
- Study of AT-752 in Healthy SubjectsCompletedPhase 1Atea Pharmaceuticals, Inc.NCT04722627Written as AT-752